Director — Joseph Schocken: The filing discloses the appointment of a new independent director to the board, which is a standard governance action and not an executive management change.

Results of Operations and Financial Condition. On August 12, 2026, Omeros Corporation issued a press release announcing financial results for the three and six months ended June 30, 2026. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or oth…

Other Events. As previously disclosed, on July 2, 2026, Omeros Corporation (the “Company”) entered into privately negotiated agreements with certain holders of its 9.50% Convertible Senior Notes due 2029 (the “Notes”) under which the Company agreed to repurchase a portion of the outstanding Notes following completion of an averaging period. The Company completed the repurchase of approximately $14.5 million aggregate principal amount of Notes on July 20, 2026, for a total purchase price, incl…

Other Events. Expected Completion of Previously Disclosed Note Repurchases As previously disclosed, on June 17, 2026, Omeros Corporation (the “Company”) entered into privately negotiated agreements with certain holders of its 9.50% Convertible Senior Notes due 2029 (the “Notes”) under which the Company agreed to repurchase a portion of the outstanding Notes. The applicable averaging period has been completed and the Company expects to complete the repurchase of $16.0 million aggregate princip…

Other Events. On June 17, 2026, Omeros Corporation (the “Company”) entered into privately negotiated agreements with certain holders of its 9.50% Convertible Senior Notes due 2029 (the “Notes”) under which it agreed to repurchase Notes having an aggregate principal amount of up to approximately $16.0 million for a total purchase price, inclusive of accrued and unpaid interest and all other obligations, of up to approximately $34.0 million, subject in each case to adjustment based on the tradi…

Results of Operations and Financial Condition. On May 13, 2026, Omeros Corporation issued a press release announcing financial results for the three months ended March 31, 2026. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise sub…

Results of Operations and Financial Condition. On March 31, 2026, Omeros Corporation issued a press release announcing financial results for the three and twelve months ended December 31, 2025. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,…

of Form 8-K, this filing is being made to report that at December 31, 2025, we had approximately $171.5 million of cash and short-term investments available for operations. This figure is preliminary and unaudited. It is subject to completion of the Company’s customary financial closing procedures and adjustments. The information in this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subj…

above are filed as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference: ● the Company’s unaudited pro forma condensed consolidated balance sheet as of September 30, 2025; ● the Company’s unaudited pro forma consolidated statement of operations and comprehensive income (loss) for fiscal year ended December 31, 2024; and ● the Company’s unaudited pro forma condensed consolidated statement of operations and comprehensive loss for the nine-month period ended Septe…

above. In addition, Omeros can receive (i) up to a total of $510 million in one-time milestone payments upon the first achievement by Novo Nordisk or its affiliates or sublicensees of each of the development and approval milestone events as set forth in the Agreement and (ii) up to $1.3 billion in one-time milestone payments upon the first achievement by Novo Nordisk or its affiliates or sublicensees of certain sales-based milestone events as set forth in the Agreement. The upfront cash recei…

Results of Operations and Financial Condition. On November 13, 2025, Omeros Corporation issued a press release announcing financial results for the three and nine months ended September 30, 2025. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended…

Entry into a Material Definitive Agreement. Asset Purchase and License Agreement On October 10, 2025, Omeros Corporation (the “Company”) entered into an Asset Purchase and License Agreement (the “Agreement”) with Novo Nordisk Health Care AG (“Novo Nordisk”), pursuant to which Novo Nordisk will receive exclusive global rights in all indications to develop and commercialize zaltenibart (OMS906), the Company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine prote…

Results of Operations and Financial Condition. On August 14, 2025, Omeros Corporation issued a press release announcing financial results for the three and six months ended June 30, 2025. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or oth…

Other Events. Registered Direct Offering On July 24, 2025, Omeros Corporation (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Polar Asset Management Partners (the “Purchaser”) pursuant to which the Company agreed to issue and sell to the Purchaser in a registered direct offering (the “Offering”) an aggregate of 5,365,853 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a price per Share of $4.1…

Results of Operations and Financial Condition. On March 31, 2025, Omeros Corporation issued a press release announcing financial results for the three months and year ended December 31, 2024. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…

Results of Operations and Financial Condition. On November 13, 2024, Omeros Corporation issued a press release announcing financial results for the three and nine months ended September 30, 2024. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended…

Results of Operations and Financial Condition. On August 7, 2024, Omeros Corporation issued a press release announcing financial results for the three and six months ended June 30, 2024. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or othe…

Vice President, Finance, Chief Accounting Officer and Treasurer — Michael A. Jacobsen: Michael A. Jacobsen is retiring from his positions and will be succeeded by David J. Borges.

Entry into a Definitive Material Agreement.

Other Events. As described above, on the Closing Date, the Company repurchased $118.1 million aggregate principal amount of the 2026 Notes through separate, privately negotiated agreements with the Noteholders. If the Company enters into agreements for additional repurchases of 2026 Notes within six months of the Closing Date with pricing or other terms that are more favorable than those received by the Noteholders, the Company agreed to pay the Noteholders the difference between the more fav…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On June 3, 2024 (the “Closing Date”), Omeros Corporation (the “Company”) with certain subsidiaries, as guarantors, entered into a Credit and Guaranty Agreement (the “Credit Agreement”) with certain funds managed by Athyrium Capital Management, LP (collectively, “Athyrium”) and certain funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge”) as lenders (tog…

Results of Operations and Financial Condition. On May 15, 2024, Omeros Corporation issued a press release announcing financial results for the three months ended March 31, 2024. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise sub…

Results of Operations and Financial Condition. On April 1, 2024, Omeros Corporation issued a press release announcing financial results for the three months and year ended December 31, 2023. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On February 1, 2024, Omeros Corporation (“Omeros” or the “Company”) entered into an amended and restated royalty purchase agreement (the “Amendment”) with DRI Healthcare Acquisitions LP (“DRI”) providing for the acquisition by DRI of an expanded interest in certain royalty payments based on annual net sales of Omeros’ former ophthalmologic product OMIDRIA® (the “Purchased Receiva…

Entry into a Definitive Material Agreement.